RxDoctor Payments Data

Kevin Deregnier

Family Medicine · Winterset, IANPI 1184708687

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $53,069 of the $67,949 with a category attached, or 78.1%. Novo Nordisk accounts for 83.8% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2019 at $17,825 and has fallen 99.1% since, to $153 in 2025. Among family medicine clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$67,949in general payments, 2019–2025

Across 865 payments — averaging $78.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$57K
  • AbbVie$2K
  • Pfizer$904
  • AstraZeneca$897
  • Amgen$816
  • Boehringer Ingelheim$744
  • plus $5K from 39 others

What the payments were for

  • Speaking & faculty fees$53,06978%
  • Travel & lodging$2,3783%
  • Food & beverage$12,30118%
  • Education$2010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$67,949 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide169$194,392
EliquisApixaban176$114,736
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$88,503
JardianceEmpagliflozin80$59,546
MounjaroTirzepatide26$29,002
Tresiba Flextouch U-200Insulin Degludec24$26,705
XareltoRivaroxaban39$25,136
CreonLipase/Protease/Amylase14$22,867
Tresiba Flextouch U-100Insulin Degludec56$20,704
JanuviaSitagliptin Phosphate30$18,688
RybelsusSemaglutide15$14,051
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$13,502
Victoza 3-PakLiraglutide16$12,061
Breo ElliptaFluticasone/Vilanterol21$11,416
TradjentaLinagliptin16$11,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$56,938$208,443184 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$406$116,260170 claims
PfizerEliquis$904$114,736176 claims
Boehringer IngelheimJardiance, Tradjenta$744$70,94196 claims
AbbVieCreon, Linzess$2,297$33,22632 claims
Lilly USA, LLCMounjaro$479$29,00226 claims
Johnson & JohnsonXarelto$150$25,13639 claims
MerckJanuvia$195$18,68830 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$218$8,32315 claims
AstraZenecaFarxiga$897$6,17723 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$3,326455 claims
Sumitomo Pharma America, Inc.Gemtesa$18$3,16313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Winterset

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →